Financial Performance - Total revenue for the six months ended June 30, 2024, was $16,020,000, compared to $20,000 for the same period in 2023[12]. - Net income for the six months ended June 30, 2024, was $11,231,561, compared to a net loss of $(4,482,349) for the same period in 2023, representing a significant turnaround[19]. - Net loss for the three months ended June 30, 2024, was $2,221,646, compared to a net loss of $2,613,813 for the same period in 2023, representing a 15% improvement[12]. - The company reported a comprehensive loss of $2,203,007 for the three months ended June 30, 2024, compared to a comprehensive loss of $2,624,262 for the same period in 2023, reflecting a 16% improvement[12]. - Net loss for the six months ended June 30, 2024, was $11.23 million, a decrease in loss of $15.71 million compared to a net loss of $4.48 million in the same period in 2023[122]. Operating Expenses - Operating expenses for the three months ended June 30, 2024, were $2,564,887, a decrease of 2.6% from $2,633,012 in the same period of 2023[12]. - Operating expenses for the six months ended June 30, 2024, totaled $5.34 million, an increase of $0.79 million from $4.55 million in the same period in 2023[122]. - Kiora's general and administrative expenses increased by $0.47 million for the six months ended June 30, 2024, primarily due to higher professional fees and personnel-related costs[123]. - Research and development expenses for the six months ended June 30, 2024, were $2,400,339, compared to $1,830,382 for the same period in 2023, showing an increase of 31%[12]. - Research and Development expenses increased by $0.6 million, primarily due to UC licensing payments of $0.7 million and drug substance testing costs of $0.6 million[124]. Cash and Investments - Cash, cash equivalents, and restricted cash at the end of the period were $6,579,573, compared to $7,955,800 at the end of June 30, 2023[19]. - As of June 30, 2024, Kiora Pharmaceuticals had unrestricted cash and cash equivalents of $6.6 million and short-term investments of $21.2 million, with an accumulated deficit of $135.7 million[27]. - The total cash, cash equivalents, and restricted cash amounted to $6.58 million as of June 30, 2024, compared to $2.46 million on December 31, 2023, indicating a significant increase[45]. - As of June 30, 2024, the company had unrestricted cash and cash equivalents totaling $6.6 million, compared to $2.5 million at December 31, 2023[128]. - Cash on hand and short-term investments at June 30, 2024, totaled approximately $27.8 million, which is expected to fund operations into 2027[133]. Equity and Stock - Total stockholders' equity increased to $33,101,673 as of June 30, 2024, compared to $10,155,509 as of June 30, 2023, reflecting a growth of approximately 226%[13]. - The weighted average shares outstanding for basic earnings per share increased to 4,170,627 for the three months ended June 30, 2024, compared to 365,530 for the same period in 2023[12]. - The company issued 1,755,556 shares of common stock from a private placement, contributing $158,000 to stock amount and $13,650,815 to additional paid-in capital[17]. - The company raised $14,998,865 from a private placement, net of offering costs of $1,190,049, during the first half of 2024[19]. - The company raised net proceeds of approximately $13.8 million in a private placement offering that closed on February 5, 2024[127]. Collaboration and Revenue Recognition - The company had no collaboration revenue for the three months ended June 30, 2024, while it recorded $16,000,000 in collaboration revenue for the six months ended June 30, 2024[12]. - Kiora recognized a license access fee of $16.0 million in the first quarter of 2024 from a strategic agreement with Théa Open Innovation for the development of KIO-301[40]. - Kiora Pharmaceuticals recognized $16 million in collaboration revenue from a strategic development and commercialization agreement with Théa Open Innovation in January 2024[109]. - The company has not recorded any deferred revenue balance as of June 30, 2024, indicating no amounts received prior to satisfying revenue recognition criteria[35]. Future Outlook and Development - The company is focused on developing therapies for ophthalmic diseases, with ongoing efforts in research and development[21]. - The company plans to initiate a Phase 2 trial for KIO-301 later in 2024, expanding its development to include late-stage Choroideremia and Stargardt disease[110]. - Kiora is designing a Phase 2 clinical trial for KIO-104, expected to start in early 2025, targeting Posterior Non-Infectious Uveitis[111]. - The company anticipates needing additional financing to support future operations and product commercialization efforts[126]. - The company expects to incur significant expenses and increasing operating losses for the foreseeable future as it seeks partnerships for product development[130]. Assets and Liabilities - Total assets measured at fair value amounted to $26,209,635, with cash equivalents at $4,966,964 and short-term investments at $21,242,671[55]. - The Company has a total lease liability of $82.322 million, with future annual minimum lease payments totaling $92.835 million as of June 30, 2024[86]. - The maximum obligation for contingent consideration from acquisitions totals $18.799 million, with a current fair value estimated at $5.237 million[100]. - Contingent consideration liabilities increased to $5,236,999 from $5,128,959, a rise of 2.1%[57]. - The discount rate for contingent consideration increased to 15.0% from 13.1%[58].

Core Insights - Kiora Pharmaceuticals reported its second quarter 2024 financial results and provided updates on its retinal disease drug development pipeline, specifically focusing on two Phase 2 studies for KIO-301 and KIO-104 [3][4]. Financial Performance - The company ended the second quarter with $27.8 million in cash, cash equivalents, and short-term investments, along with an additional $3.7 million in near-term receivables from R&D reimbursements and tax credits, providing a runway into 2027 [3][11]. - Revenue for the second quarter was $20,000, attributed to a grant from the Choroideremia Research Foundation, compared to no revenue in the same quarter of 2023 [12]. - Kiora's net loss for the second quarter was $2.2 million, a decrease from a net loss of $2.6 million in the same period last year, primarily due to expense credits related to KIO-301 [15]. Drug Development Pipeline - KIO-301, a small molecule photoswitch for treating inherited retinal diseases, is advancing towards a Phase 2 trial (ABACUS-2) with a focus on refining approvable endpoints through interactions with the FDA and European regulators [5][6]. - KIO-104, aimed at treating multiple retinal inflammatory diseases, is set to initiate a Phase 2 trial (CLARITY) early next year, building on positive Phase 1b results [7][10]. - The company received Orphan Medicinal Product Designation from the European Medicines Agency for KIO-301 and reported significant functional MRI results from the ABACUS-1 trial [8][9]. Corporate Developments - Kiora promoted Melissa Tosca to Chief Financial Officer and appointed Lisa Walters-Hoffert as an independent board member [10]. - The company anticipates completing clinical validation of functional vision endpoints for KIO-301 and initiating the Phase 2 CLARITY study for KIO-104 in the second half of 2024 [10].

Group 1 - Kiora Pharmaceuticals will participate in the Jones Trading Healthcare Seaside Summit on July 15, 2024, at 6:15 PM Eastern Time [10] - The company invites shareholders to submit questions regarding clinical development plans, investigational therapies, and financials through a dedicated Q&A portal from July 16 to July 19, 2024 [3] - The presentation will be available live and on-demand for 90 days on Kiora's Investor Relations homepage [6] Group 2 - Kiora Pharmaceuticals is a clinical-stage biotechnology company focused on developing treatments for orphan retinal diseases [7] - KIO-301 is being developed for retinitis pigmentosa, choroideremia, and Stargardt disease, aiming to restore vision in patients with retinal degeneration [7] - KIO-104 is being developed for posterior non-infectious uveitis as a next-generation, non-steroidal, immuno-modulatory small-molecule inhibitor [7]

Core Insights - Kiora Pharmaceuticals has appointed Lisa Walters-Hoffert as an independent member of its Board of Directors, bringing extensive experience in biotech and investment banking [16][7] - The company is focused on advancing its pipeline of investigational treatments for retinal diseases, specifically KIO-301 and KIO-104 [2][13] - Ken Gayron will step down from the Board, marking a significant transition as Kiora continues its strategic growth [16][11] Company Overview - Kiora Pharmaceuticals is a clinical-stage biotechnology company dedicated to developing and commercializing products for orphan retinal diseases [13] - KIO-301 is aimed at treating retinitis pigmentosa, choroideremia, and Stargardt disease, while KIO-104 targets posterior non-infectious uveitis [13] - The company has reported promising data from KIO-301 and established a strategic partnership for co-development and commercialization [11] Leadership and Governance - Lisa Walters-Hoffert will serve as chair of the audit committee and a member of the compensation committee [16] - She has over 25 years of experience in investment banking, particularly with small-cap public companies in life sciences and technology [7] - Walters-Hoffert has held significant roles in various financial institutions, including Roth Capital Partners and Citicorp Securities [7] Financial Position - Kiora has capitalized the company with an expected runway for at least the next two years, allowing for continued investment in its therapies [11] - The company is positioned to leverage its financial resources to advance the development of KIO-104 [11]

. Vitreoretinal Surgeon and Key Thought Leader Roger Goldberg, M.D., Joins Kiora Pharmaceuticals' Scientific Advisory Board Encinitas, California--(Newsfile Corp. - June 25, 2024) - Kiora Pharmaceuticals (NASDAQ: KPRX) has appointed Roger A. Goldberg, MD, MBA, a vitreoretinal surgeon at Bay Area Retina Associates (BARA) to its Scientific Advisory Board. As an advisor, Dr. Goldberg will contribute scientific insights and valued clinical perspectives to aid Kiora's development of new therapeutics to address r ...

Core Insights - The article emphasizes the importance of value investing as a preferred strategy for identifying strong stocks in various market conditions [2] - Kiora Pharmaceuticals (KPRX) is highlighted as a stock to watch, currently holding a Zacks Rank of 2 (Buy) and a Value grade of A [3] Valuation Metrics - KPRX has a Price-to-Book (P/B) ratio of 0.45, significantly lower than the industry average of 1.27, indicating potential undervaluation [4] - The stock's P/CF (Price-to-Cash Flow) ratio stands at 7.31, compared to the industry's average of 10.25, further suggesting that KPRX may be undervalued [5] Earnings Outlook - The combination of KPRX's strong valuation metrics and positive earnings outlook positions it as an impressive value stock in the current market [6]

Encinitas, California--(Newsfile Corp. - May 20, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (KPRX) ("Kiora" or the "Company"), will participate in two upcoming investor conferences that will be available to investors live with the replay available on-demand. On Wednesday May 22, at 3:00 pm Eastern Time, Kiora's Executive Vice President of Finance, Melissa Tosca, will participate in the WeBull Corporate Connect Biotech Investment Webinar. The presentation will be available live from this registration ...

Exhibit 99.1 Kiora Pharmaceuticals Reports First Quarter Results; Update on Pipeline of Drugs Targeting Retinal Disease Phase 2 trial for KIO-301 for the treatment of retinitis pigmentosa, in partnership with Théa Open Innovation, expected to be initiated in Q4 2024 Phase 2 clinical trial for KIO-104 for retinal inflammation expected to begin in 2025 "In the first quarter, we executed a strategic partnership with TOI, which included a $16 million upfront payment, and raised $15 million from an equity offeri ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File No. 001-36672 KIORA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Its Charter) (State or o ...

WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 25, 2024 KIORA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware UNITED STATES SECURITIES AND EXCHANGE COMMISSION (State or other jurisdiction of incorporation) 001-36672 98-0443284 (Commission File Number) (IRS Employer Identification No.) 332 Encinitas Blvd. Suite 102 Encinitas, CA 92024 (858) 224-960 ...